Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TRI

Inoviv Launches NeuroKey-3tm, A Quantitative Multiplexed IP-MS Assay to Measure Key Low-Level Markers in Neurodegeneration


LONDON, March 1, 2024 /PRNewswire/ -- Biomarker pioneer, Inoviv, announces the launch of its proprietary NeuroKey-3tm assay, an end-to-end service offering to measure key low-level markers in neurodegeneration in human plasma. The launch of NeuroKey-3tm signifies an important milestone in Inoviv's mission to generate novel molecular insights that transform drug development and healthcare globally. Inoviv will unveil NeuroKey-3tm at AD/PD 2024 on March 5, 2024.

NeuroKey-3tm is the world's first commercially available disease-targeted assay providing absolute quantification from plasma of a unique set of proteins linked to Alzheimer's Disease and Dementia. The comprehensive assay and end-to-end service delivers highly robust and reproducible data to quantify low-level analytes and provides clinical researchers with a full biomarker report containing statistical analysis, graphical data representations, correlation matrices, and quantitative values.

"NeuroKey-3 significantly accelerates clinical trial timelines and offers neurological drug developers a game-changing biomarker strategy that can measure proteins which pharmaceutical companies care about, at the precision needed to enable decision-making and FDA submissions," said Inoviv CEO & co-founder Michael Dove. "NeuroKey-3 provides highly accurate and fully quantitative insights into proteins linked to neurodegeneration and can be adapted to provide definitive data into post-translational modifications, other proteins, lipids, and metabolites."

For more information about NeuroKey-3tm, find us at:

About Inoviv

Our mission is to generate novel molecular insights that transform drug development and healthcare globally. We work with leading pharma and biotech companies to deliver robust and quantitative biomarker analysis to accelerate the development of life-changing treatments.

We are setting the standard for targeted proteomics. Whether you want to discover treatment-responsive biomarkers, create a custom panel, scale up and validate your own assay for clinical studies, or take advantage of our pre-validated panels, we're your trusted proteomics partners. https://www.inoviv.com/

SOURCE Inoviv


These press releases may also interest you

at 09:05
GE HealthCare Receives FDA Clearance for Portrait VSM, Building on Its Growing Ecosystem of Connected Patient Monitoring Solutions
GE HealthCare today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Portrait VSM vital signs monitor that can provide clinicians with an accurate view of patient vital signs to support...

at 09:05
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Merck , known as MSD outside of the United States and Canada, today announced results from STRIDE-10, a Phase 3 trial evaluating V116, the company's investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European...

at 09:00
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
? 2023 marked by Ceapro's achievement of key milestones and progress toward its next phase of growth ? R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the...

at 09:00
Deloitte Acquires Gryphon Scientific Business to Expand Security, Science and Public Health Capabilities
Deloitte announced that it has acquired substantially all of the assets of Gryphon Scientific, LLC (Gryphon), a leader in biosafety, biosecurity, and all-hazards preparedness and response, with experience in using artificial intelligence (AI) to...

at 09:00
IMAGENET DESIGNATED AS PREFERRED VENDOR FOR THE ASSOCIATION FOR COMMUNITY AFFILIATED PLANS
Imagenet, LLC, a leading healthcare operations partner, announced their acceptance as a Preferred Vendor for the Association for Community Affiliated Plans (ACAP). ACAP represents 79 health plans that collectively serve more than 25 million covered...

at 09:00
Top Atlanta Dental Practice, Marietta Dental Professionals, is Delivering a New High-Tech AI Dental Patient Experience
State-of-the-art practice, Marietta Dental Professionals, has announced a groundbreaking partnership with the leader in AI (artificial intelligence) dentistry, Pearl Inc. http://www.hellopearl.com. This collaboration will bring a new level of...

More news about Health...


News published on and distributed by: